About This Treatment

Myeloma Clinical Trials

Phase 1b/2 Study of Selinexor (KPT-330) in Combination w/ Backbone Treatments for Relapsed/Refractory Multiple Myeloma (STOMP)

This study will independently assess the efficacy and safety of three combination therapies for the treatment of patients with relapsed/refractory multiple myeloma (RR MM): selinexor + dexamethasone + pomalidomide (SdP) and selinexor + dexamethasone + bortezomib (SdB), selinexor + dexamtheasone + lenalidomide.

Learn more about this trial

A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma

The purpose of this study is to test the safety of a combination of study drugs called selinexor (KPT-330) and ixazomib (MLN9708) with a low dose of dexamethasone.

Learn more about this trial

Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Phase I: The primary purpose of this study phase is to determine the best dose also referred to as the maximum tolerated dose (MTD) of Selinexor when used in combination with high-dose melphalan as a conditioning regimen for hematopoietic cell transplant. Phase II: The primary purpose of this study phase is to assess the complete response (CR) conversion rate.

Learn more about this trial

Treatment Information
Developed By

Karyopharm Therapeutics

Treatment Classifications
Additional Names
  • KPT-330

Create Your Account

Create your account today and get matched to myeloma treatments and trials around the US.

  • Find treatments with eligible clinical trials.
  • Get a second opinion from a myeloma specialist.
  • Receive alerts when new treatments become available.
  • Our services are always free for patients and HIPAA compliant.

Create Account

Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST